--Smaller 6mm Diameter and Other Product Enhancements are
Designed to Increase Patient Comfort and Improve Physician
Ease-of-Use--
MARLBOROUGH, Massachusetts,
Nov. 14, 2016 /PRNewswire/
-- Hologic, Inc. (Nasdaq: HOLX) today announced the launch of
its next-generation NovaSure® 6mm global endometrial
ablation (GEA) system, the NovaSure® ADVANCED system.
The system has been CE-marked and is being launched in Europe, Canada and Australia.
The NovaSure system reduces abnormal uterine bleeding by
applying radiofrequency energy to the endometrium and gently
removing the lining of the uterus in two minutes or
less.1 The enhancements in the NovaSure ADVANCED product
are designed with the patient and physician in mind, offering a 6mm
diameter to improve patient comfort and physician ease-of-use while
maintaining the clinical efficacy of the trusted NovaSure
system.
As an alternative to the 8mm NovaSure device, the current
standard of care, the 6mm device requires less dilation based on a
smaller sheath size. This can improve patient comfort, especially
for patients who have difficulty dilating. In addition, the new
NovaSure device is designed with an acorn-like shaped cervical seal
with 13% more "working length" than the previous product. The new
device is also equipped with rounded Smooth Access™ tips that
simplify insertion, and a blue handle that serves as a useful
reminder for how the device should be inserted.
"In addition to the new system providing a high level of patient
and physician satisfaction, it's important to note that the slender
diameter will allow physicians to perform more procedures
in-office," said Dr. Henrik
Skensved, a Consultant Gynecologist from Denmark who was one of the first clinicians to
use the new NovaSure ADVANCED system. "The introduction of the 6mm
device gives physicians the ability to treat patients in a more
comfortable setting, while maintaining the efficacy we have trusted
from the NovaSure system for more than 10 years."
The NovaSure system is used to treat women with abnormal uterine
bleeding, a condition that affects one in five women2
and can be lifestyle-restricting. Endometrial ablation with
NovaSure is a one-time procedure that can be performed in the
doctor's office. The procedure is safe and effective, dramatically
reducing or stopping menstrual bleeding in 90% of women. More
than two million women have chosen the NovaSure procedure to treat
abnormal uterine bleeding.3
"Our next-generation NovaSure ADVANCED system is the same safe
and efficacious NovaSure device that physicians and patients have
relied on for years, now thoughtfully designed with the
enhancements our customers have been requesting," said Tom O'Neill, Hologic's Division President, GYN
Surgical Solutions. "The evolution of the NovaSure system signals
our ongoing commitment to addressing our customers' needs and
improving the overall patient experience by offering quick and
effective solutions to treat excessive bleeding."
About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal health. With
a unified suite of technologies and a robust research and
development program, Hologic is dedicated to The Science of Sure.
For more information on Hologic, visit www.hologic.com.
Hologic, NovaSure, The Science of Sure, and associated logos are
trademarks and/or registered trademarks of Hologic, Inc. and/or its
subsidiaries in the United States
and/or other countries. All other trademarks, registered
trademarks, and product names are the property of their respective
owners.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient, as the actual effect of the use of the products
can only be determined on a case-by-case basis. In addition, there
can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or
statements are based.
NovaSure ADVANCED has been CE-marked and is being launched in
Europe, Canada and Australia. NovaSure ADVANCED is not approved
for marketing in the United
States. This information is not intended as a product
solicitation or promotion where such activities are prohibited. For
specific information on what products are available for sale in a
particular country, please contact a local Hologic sales
representative or write to womenshealth@hologic.com.
Media Contact:
Jane
Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact:
Michael
Watts
858.410.8588
michael.watts@hologic.com
References
1 Gimpelson, R. Ten-year Literature Review of Global Endometrial
Ablation with NovaSure Device. International Journal of Women's
Health 2014:6 269-80.
2 Centers for Disease Control and Prevention. Blood disorders in
women: heavy menstrual bleeding.
http://www.cdc.gov/ncbddd/blooddisorders/women/menorrhagia.html.
Accessed September 24, 2015.
3 Hologic Inc., Data on file, 2014.